RxDoctor Payments Data

Nicholas Capaldo, MD

Internal Medicine · Mansfield, OHNPI 1932662400

Payments from drug & device makers

$4,712in general payments, 2019–2025

Across 240 payments — averaging $19.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$765
  • GSK$554
  • Novo Nordisk$495
  • Lundbeck LLC$428
  • AstraZeneca$377
  • Lilly USA, LLC$186
  • plus $2K from 30 others

What the payments were for

  • Food & beverage$4,712100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,712 in reported general payments places this provider in the 85th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$47,447
Medicare patients
334
Services billed
574

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban75$84,325
OzempicSemaglutide49$63,862
TrulicityDulaglutide19$34,500
JardianceEmpagliflozin24$30,365
CreonLipase/Protease/Amylase11$18,796
XareltoRivaroxaban12$18,539
JanuviaSitagliptin Phosphate17$17,531
MyrbetriqMirabegron19$14,578
LinzessLinaclotide11$13,796
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$12,398
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,469
Advair HfaFluticasone Propion/Salmeterol16$6,047
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$4,418
SymbicortBudesonide/Formoterol Fumarate19$3,442
Celecoxib58$3,082

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$179$84,32575 claims
Novo NordiskOzempic$495$63,86249 claims
Lilly USA, LLCTrulicity$186$34,50019 claims
AbbVieCreon, Linzess, Synthroid$765$34,00249 claims
Boehringer IngelheimJardiance$84$30,36524 claims
Johnson & JohnsonXarelto$172$18,53912 claims
MerckJanuvia$17$17,53117 claims
Astellas Pharma US IncMyrbetriq$86$14,57819 claims
GSKTrelegy Ellipta$554$12,39811 claims
AstraZenecaBreztri Aerosphere, Symbicort$377$10,91131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Mansfield

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →